

Contents

Preface	vii
1 Basics of Personalized Medicine	1
Definition of Personalized Medicine	1
History of Medical Concepts Relevant to Personalized Medicine.....	3
Molecular Biological Basis of Personalized Medicine.....	5
The Human Genome.....	6
Chromosomes	6
Genes.....	7
The Genetic Code	7
Gene Expression	8
DNA Sequences and Structure.....	8
Single Nucleotide Polymorphisms.....	9
Genotype and Haplotypes.....	9
Genetic Variations in the Human Genome.....	9
Insertions and Deletions in the Human Genome	10
Large Scale Variation in Human Genome.....	11
Variation in Copy Number in the Human Genome.....	11
Structural Variants in the Human Genome	12
Mapping and Sequencing of Structural Variants from Human Genomes.....	13
1,000 Genomes Project	14
Human Variome Project.....	15
Basics Technologies for Developing Personalized Medicine	15
Definitions of Technologies Relevant to Personalized Medicine	15
Problems with the ICH Definitions of Pharmacogenomics and Pharmacogenetics.....	16
Relationship of Various Technologies to Personalized Medicine.....	16
Conventional Medicine vs. Personalized Medicine	17
Genetic Basis of Personalized Medicine.....	18
Genetic Medicine	18
Human Disease and Genes.....	18

Genetic and Environmental Interactions in Etiology of Human Diseases	19
Mass Analysis of DNA from Whole Populations	19
Role of Genetics in Development of Personalized Medicines.....	20
Genetic Databases.....	20
Genetic Epidemiology	21
Limitations of Medical Genetics and Future Prospects	22
Genetics vs. Epigenetics	22
Role of Systems Biology in Personalized Medicine.....	22
Systems Pharmacology	24
Systems Medicine	24
A Personalized Approach to Environmental Factors in Disease	25
Reclassification of Diseases.....	26
Summary	27
2 Molecular Diagnostics as Basis of Personalized Medicine	29
Introduction.....	29
Molecular Diagnostic Technologies	29
DNA Sequencing	30
Biochips and Microarrays	30
DNA Biochip Technology for Developing Personalized Medicine.....	30
Role of Protein Biochips in Personalized Medicine	34
Cytogenetics.....	35
Molecular Cytogenetics as Basis for Personalized Medicine.....	35
Cytomics as a Basis for Personalized Medicine	36
SNP Genotyping	37
Technologies for SNP Analysis	37
Applications of SNPs Relevant to Personalized Medicine	37
Concluding Remarks on SNP Genotyping	39
Haplotyping.....	40
HapMap Project	41
Predicting Drug Response with HapMap	42
Nanodiagnostics for Personalized Medicine.....	42
Cantilevers for Personalized Medical Diagnostics	43
Nanopore-Based Technology for Single Molecule Identification	44
Application of Proteomics in Molecular Diagnosis.....	44
Comparison of Proteomic and Genomic Approaches in Personalized Medicine	44
Gene Expression Profiling	45
DNA Microarrays for Gene Expression Studies.....	46
Analysis of Single-Cell Gene Expression.....	47
Gene Expression Profiling Based on Alternative RNA Splicing	47
Molecular Imaging and Personalized Medicine	48
Monitoring In Vivo Gene Expression by Molecular Imaging	49
Glycomics-Based Diagnostics	49

Combination of Diagnostics and Therapeutics	50
Point-of-Care Diagnosis.....	50
Point-of-Care Diagnosis of Infections	52
Advantages vs. Disadvantages of Point-of-Care Diagnosis.....	52
Future Prospects of Point-of-Care Diagnosis	53
Genetic Testing for Disease Predisposition	53
Personal Genetic Service	54
Role of Diagnostics in Integrated Healthcare	54
Concept of Integrated Healthcare	54
Components of Integrated Healthcare.....	55
Screening.....	55
Disease Prediction.....	55
Early Diagnosis	55
Prevention	56
Therapy Based on Molecular Diagnosis	56
Monitoring of Therapy.....	56
Advantages and Limitations of Integrated Healthcare.....	56
Future of Molecular Diagnostics in Personalized Medicine.....	57
Summary	57
3 Role of Biomarkers in Personalized Medicine	59
Introduction.....	59
Technologies for Discovery of Biomarkers	60
Systems Biology Approach to Biomarker Identification.....	60
Epigenomic Technologies.....	60
Discovery of Methylation Biomarkers.....	62
Proteomic Strategies for Biomarker Identification	62
Proteomic Technologies for Detection of Biomarkers	
in Body Fluids.....	63
Biomarkers for Diagnostics	63
Biomarkers for Drug Development.....	64
Use of Biomarkers for Developing MAb Therapy in Oncology.....	64
Biobanking, Biomarkers and Personalized Medicine	65
Expression Signatures as Diagnostic/Prognostic Tools	66
Biomarkers for Monitoring Response to Therapy	66
Drug Rescue by Biomarker-Based Personalized Medicine	67
Future Role of Biomarkers in Personalized Medicine	68
Summary	68
4 Pharmacogenetics	69
Basics of Pharmacogenetics.....	69
Role of Molecular Diagnostics in Pharmacogenetics	70
Role of Pharmacogenetics in Pharmaceutical Industry	71
Study of the Drug Metabolism and Pharmacological Effects.....	71
Causes of Variations in Drug Metabolism	72

Enzymes Relevant to Drug Metabolism	72
Pharmacogenetics of Phase I Metabolism	73
Cyp450.....	73
P450 CYP 2D6 Inhibition by Selective Serotonin Reuptake Inhibitors (SSRIs)	75
Cytochrome P450 Polymorphisms and Response to Clopidogrel	76
Lansoprazole and Cytochrome P450	76
Glucose-6-Phosphate Dehydrogenase	77
Pharmacogenetics of Phase II Metabolism	78
<i>N</i> -Acetyltransferase	78
Uridine Diphosphate-Glucuronosyltransferase.....	79
Measurement of CYP Isoforms	79
Polymorphism of Drug Transporters	80
Genetic Variation in Drug Targets.....	81
Polymorphisms of Kinase Genes	82
Effect of Genetic Polymorphisms on Response of Disease to Drugs	82
Ethnic Differences in Drug Metabolism	83
Gender Differences in Pharmacogenetics	83
Role of Pharmacogenetics in Drug Safety	84
Adverse Drug Reactions	84
ADRs in Children	84
Genetically Determined ADRs	85
ADRs of Chemotherapy.....	86
Malignant Hyperthermia.....	87
Pharmacogenetics of Clozapine-Induced Agranulocytosis.....	87
Role of Pharmacogenetics in Warfarin Therapy	88
Role of Pharmacogenetics in Carbamazepine Therapy	89
Role of Pharmacogenetics in Statin Therapy.....	89
FDA Consortium for Genetic Biomarkers of Serious Adverse Events	90
Therapeutic Drug Monitoring, Phenotyping, and Genotyping	91
Therapeutic Drug Monitoring.....	91
Phenotyping	91
Genotyping.....	93
Genotyping vs. Phenotyping.....	93
Phenomics	94
Limitations of Genotype-Phenotype Association Studies	95
Molecular Toxicology in Relation to Personalized Medicines	95
Toxicogenomics	95
Gene Expression Studies.....	96
Genomics and the Prediction of Xenobiotic Toxicity.....	97
Pharmacogenetics in Clinical Trials	97
Clinical Implications of Pharmacogenetics	98
Application of CYP450 Genotyping in Clinical Practice.....	98
Genotype-Based Drug Dose Adjustment.....	98

Examples of use of Pharmacogenetics in Clinical Pharmacology.....	99
Linking Pharmacogenetics with Pharmacovigilance	100
Genetic Susceptibility to ADRs	100
Linking Genetic Testing to Postmarketing ADR Surveillance	100
Recommendations for the Clinical Use of Pharmacogenetics.....	101
Limitations of Pharmacogenetics.....	101
Future Role of Pharmacogenetics in Personalized Medicine	102
Summary	102
5 Pharmacogenomics	105
Introduction.....	105
Basics of Pharmacogenomics	105
Pharmacogenomics and Drug Discovery	107
Preclinical Prediction of Drug Efficacy	108
Pharmacogenomics and Clinical Trials.....	109
Impact of Genetic Profiling on Clinical Studies	109
Limitations of the Pharmacogenomic-Based Clinical Trials	111
Pharmacogenomic Aspects of Major Therapeutic Areas.....	112
Oncogenomics.....	112
Oncogenes.....	112
Tumor Suppressor Genes	113
Cardiogenomics	113
Neurogenomics	117
Pharmacogenomics of AD	117
Pharmacogenomics of Depression.....	118
Pharmacogenomics of Schizophrenia.....	118
Summary	119
6 Role of Pharmacoproteomics	121
Basics of Proteomics.....	121
Proteomic Approaches to the Study of Pathophysiology of Diseases	122
Single Cell Proteomics for Personalized Medicine	122
Diseases Due to Misfolding of Proteins.....	123
Therapies for Protein Misfolding.....	123
Significance of Mitochondrial Proteome in Human Disease.....	124
Proteomic Technologies for Drug Discovery and Development	125
Role of Reverse-Phase Protein Microarray in Drug Discovery	125
Role of Proteomics in Clinical Drug Safety	125
Toxicoproteomics.....	126
Application of Pharmacoproteomics in Personalized Medicine.....	128
Summary	128
7 Role of Metabolomics in Personalized Medicine.....	129
Metabolomics and Metabonomics	129
Metabolomics Bridges the Gap Between Genotype and Phenotype	130

Metabolomics, Biomarkers and Personalized Medicine.....	131
Metabolomic Technologies.....	131
Urinary Profiling by Capillary Electrophoresis.....	132
Lipid Profiling.....	133
Role of Metabolomics in Biomarker Identification and Pattern Recognition.....	133
Validation of Biomarkers in Large-Scale Human Metabolomics Studies.....	134
Pharmacometabonomics.....	134
Metabonomic Technologies for Toxicology Studies.....	135
Metabonomics/Metabolomics and Personalized Nutrition.....	136
Summary.....	136
8 Personalized Biological Therapies.....	137
Introduction.....	137
Recombinant Human Proteins.....	137
Therapeutic Monoclonal Antibodies.....	138
Cell Therapy.....	138
Autologous Tissue and Cell Transplants.....	139
Stem Cells.....	139
Role of Stem Cells Derived from Unfertilized Embryos.....	139
Cloning and Personalized Cell Therapy.....	140
Use of Stem Cells for Drug Testing.....	140
Gene Therapy.....	140
Personalized Vaccines.....	141
Personalized Vaccines for Viral Diseases.....	141
Personalized Cancer Vaccines.....	142
Patient-Specific Cancer Vaccines.....	142
Antigen-Specific Vaccines.....	143
Autologous Cell Vaccines.....	143
Personalized Melanoma Vaccines.....	145
Antisense Therapy.....	145
RNA Interference.....	146
MicroRNAs.....	146
Summary.....	147
9 Development of Personalized Medicine.....	149
Introduction.....	149
Non-genomic Factors in the Development of Personalized Medicine.....	150
Personalized Medicine Based on Circadian Rhythms.....	150
Intestinal Microflora.....	151
Gut Microbiome Compared to Human Genome.....	151
Metabolic Interactions of the Host and the Intestinal Microflora.....	152
Role of Drug Delivery in Personalized Medicine.....	152
Role of Molecular Imaging in Personalized Medicine.....	153

Personalized Approach to Clinical Trials	153
Use of Bayesian Approach in Clinical Trials.....	153
Individualizing Risks and Benefits in Clinical Trials	154
Clinical Trials of Therapeutics and Companion Diagnostics	155
Role of Genetic Banking Systems and Databases	155
Role of Biobanks in the Development of Personalized Medicine	155
UK Biobank	156
Biobanking and Development of Personalized Medicine in the EU	156
CARTaGENE for Biobanks in Canada	157
Personalized Medicine Based on PhysioGenomics™ Technology	158
Role of Bioinformatics in Development of Personalized Medicine	159
Health Information Management	160
Electronic Health Records	160
Linking Patient Medical Records and Genetic Information	161
Management of Personal Genomic Data	162
Personalized Prognosis of Disease.....	162
Integration of Technologies for Development of Personalized Medicine.....	163
Summary	163
10 Personalized Therapy for Cancer.....	165
Introduction.....	165
Challenges of Cancer Classification	165
Relationships of Technologies for Personalized Management of Cancer	166
Impact of Molecular Diagnostics on the Management of Cancer	167
Analysis of RNA Splicing Events in Cancer	167
Analysis of Chromosomal Alterations in Cancer Cells	168
Cancer Classification Using Microarrays	168
Detection of Loss of Heterozygosity (LOH)	169
Diagnosis of Cancer of an Unknown Primary	170
Diagnostics for Detection of Minimal Residual Disease (MRD)	170
Fluorescent In Situ Hybridization.....	171
Gene Expression Profiling	171
Gene Expression Profiles Predict Chromosomal Instability in Tumors.....	172
Isolation and Characterization of Circulating Tumor Cells (CTCs).....	173
Modulation of CYP450 Activity for Cancer Therapy	173
Personalized Therapies Based on Oncogenic Pathway Signatures.....	174
Role of Molecular Imaging in Personalized Therapy of Cancer	175
Molecular Imaging for Personalized Drug Development in Oncology	175
Molecular Imaging as Guide to Cancer Treatment.....	176
Functional Diffusion MRI.....	177

Role of FDG-PET/CT in Personalizing Cancer Treatment	178
Tumor Imaging and Elimination by Targeted Gallium Corrole.....	179
Unraveling the Genetic Code of Cancer	179
Cancer Prognosis	180
Detection of Mutations for Risk Assessment and Prevention.....	181
Impact of Biomarkers on Management of Cancer.....	181
Predictive Biomarkers for Cancer.....	181
HER-2/neu Oncogene as a Biomarker for Cancer	182
L-asparaginase (L-ASP)Treatment of Cancer Guided by a Biomarker.....	182
Determination of Response to Therapy	183
Phenotype-Based Cell Culture Assays.....	183
Ex Vivo Testing of Tumor Biopsy for Chemotherapy Sensitivity	183
Genomic Approaches to Predict Response to Anticancer Agents	184
Gene Expression Patterns to Predict Response of Cancer to Therapy	184
Genomic Analysis of Tumor Biopsies	184
Mutation Detection at Molecular Level	185
Role of Genetic Variations in Susceptibility to Anticancer Drugs	185
Proteomic Analysis of Tumor Biopsies to Predict Response to Treatment.....	185
Real-time Apoptosis Monitoring	186
Serum Nucleosomes as Indicators of Sensitivity to Chemotherapy	186
Targeted Microbubbles to Tumors for Monitoring Anticancer Therapy.....	187
Tissue Systems Biology Approach to Personalized Management of Cancer.....	188
Targeted Cancer Therapies.....	188
Targeting Glycoproteins on Cell Surface.....	188
Targeting Pathways in Cancer.....	189
Functional Antibody-Based Personalized Therapies	189
Personalized Radiation Therapy	190
Molecular Diagnostics Combined with Cancer Therapeutics	191
Aptamers for Combined Diagnosis and Therapeutics of Cancer.....	192
Role of Nanobiotechnology in Personalized Management of Cancer	192
Design of Future Cancer Therapies	193
Screening for Personalized Anticancer Drugs	194
Role of Epigenetics in Development of Personalized Cancer Therapies	194
Personalized Therapy of Cancer Based on Cancer Stem Cells.....	195
Role of Oncoproteomics in Personalized Therapy of Cancer.....	195
Cancer Tissue Proteomics.....	196
Pharmacogenomic-Based Chemotherapy	197
Whole Genome Technology to Predict Drug Resistance.....	197

Anticancer Drug Selection Based on Molecular Characteristics of Tumor.....	197
Testing Microsatellite-Instability for Response to Chemotherapy	198
Pharmacogenetics of Cancer Chemotherapy	199
CYP1A2.....	199
Thiopurine Methyltransferase	200
Dihydropyrimidine Dehydrogenase	201
UGT1A1 Test as Guide to Irinotecan Therapy	201
Role of Computational Models in Personalized Anticancer Therapy	202
A Computational Model of Kinetically Tailored Treatment.....	202
Mathematical Modeling of Tumor Microenvironments.....	202
Molecular Profiling of Cancer	203
Drug Resistance in Cancer.....	204
Detection of Drug Resistance in Cancer by Metabolic Profiling.....	205
Determination of Chemotherapy Response by Topoisomerase Levels	205
A Systems Biology Approach to Drug Resistance in CRC	206
Management of Drug Resistance in Leukemia.....	206
Overexpression of Multidrug Resistance Gene	207
P53 Mutations	207
A Chemogenomic Approach to Drug Resistance	208
Examples of Personalized Management of Cancer	208
Personalized Management of Breast Cancer	208
Genetic Testing in Breast Cancer as a Guide to Treatment	209
Pharmacogenetics of Breast Cancer.....	210
Molecular Diagnostics in Breast Cancer.....	210
Racial Factors in the Management of Breast Cancer.....	212
Proteomics-Based Personalized Management of Breast Cancer	212
Tests for Prognosis of Breast Cancer	213
Developing Personalized Drugs for Breast Cancer.....	215
Developing Personalized Drugs for Triple-Negative Breast Cancer	216
Predicting Response to Chemotherapy in Breast Cancer	216
Prediction of Resistance to Therapy in Breast Cancer.....	219
Prediction of Adverse Reaction to RT in Breast Cancer.....	220
Prediction of Recurrence in Breast Cancer for Personalizing Therapy	220
TAILORx (Trial Assigning Individualized Options for Treatment)	222
Gene Expression Plus Conventional Predictors of Breast Cancer.....	223
Future Development of Gene Expression Microarrays for Breast Cancer	224
Personalized Management of Ovarian Cancer.....	224
Personalized Management of Hematological Malignancies.....	227

Personalized Management of Acute Leukemias.....	227
Personalized Management of Chronic Lymphocytic Leukemia.....	229
Personalized Management of Multiple Myeloma (MM).....	229
Personalized Management B Cell Lymphomas.....	231
Personalized Vaccine for Follicular Lymphoma.....	231
Personalized Management of Myelodysplasia.....	232
Personalized Management of Malignant Melanoma.....	232
Personalized Management of Gastrointestinal Cancer.....	232
Personalized Management of Esophageal Cancer.....	232
Personalized Management of CRC.....	233
Personalized Management of Lung Cancer.....	236
Determination of Outcome of EGFR Tyrosine Kinase Inhibitor Treatment.....	236
Testing for Response to Chemotherapy in Lung Cancer.....	239
Testing for Prognosis of NSCLC.....	239
Testing for Recurrence of Lung Cancer.....	240
Role of a New Classification System in the Management of Lung Cancer.....	240
Personalized Management of Prostate Cancer.....	241
Benefit of Lifestyle Changes Shown by Gene Expression Studies.....	241
Personalized Management of Brain Cancer.....	242
Genetics and Genomics of Brain Cancer.....	242
Molecular Diagnostics for Personalized Management of Brain Cancer.....	244
Personalized Chemotherapy of Brain Tumors.....	246
Biosimulation Approach to Personalizing Treatment of Brain Cancer.....	247
Personalized Therapy of Oligodendroglial Tumors.....	248
Personalized Therapy of Neuroblastomas.....	249
Personalized Management of Germ Cell Brain Tumors.....	250
Future of Cancer Therapy.....	250
Challenges for Developing Personalized Cancer Therapies.....	250
The Cancer Genome Atlas.....	251
Role of the International Cancer Genome Consortium.....	251
Using Computer and Imaging Technologies to Personalize Cancer Treatment.....	253
Integrated Genome-Wide Analysis of Cancer for Personalized Therapy.....	253
Summary.....	254
11 Personalized Management of Neurological Disorders.....	255
Introduction.....	255
Personalized Drug Development for Neurological Disorders.....	255
Personalized Drug Discovery.....	255

Molecular Imaging and CNS Drug Development.....	255
Personalized Management of AD	257
Personalized Management of PD.....	258
Discovery of Subgroup-Selective Drug Targets in PD	259
Personalized Management of Epilepsy	259
Choice of the Right AED.....	260
Pharmacogenetics of Epilepsy	260
Pharmacogenomics of Epilepsy	261
Drug Resistance in Epilepsy	262
Future Prospects for Epilepsy	263
Personalized Management of Migraine	264
Personalized Treatment of MS.....	264
MBP8298	265
Pharmacogenomics of IFN- β Therapy in MS.....	266
Future Prospects of Personalized Therapy of MS.....	267
Personalized Management of Psychiatric Disorders.....	267
Psychopharmacogenetics	267
COMT Genotype and Response to Amphetamine.....	268
Genotype and Response to Methylphenidate in Children with ADHD.....	268
Personalized Antipsychotic Therapy	269
Personalized Antidepressant Therapy	272
Pretreatment EEG to Predict Adverse Effects to Antidepressants....	273
Individualization of SSRI Treatment	273
Vilazodone with a Test for Personalized Treatment of Depression	275
Summary	275
12 Personalized Therapy of Cardiovascular Diseases	277
Introduction.....	277
Role of Cardiovascular Diagnostics in Personalized Management	277
Testing in Coronary Heart Disease	277
SNP Genotyping in Cardiovascular Disorders.....	278
Cardiovascular Disorders with a Genetic Component.....	279
Gene Variant as a Risk Factor for Sudden Cardiac Death	281
SNP Chip for Study of Cardiovascular Diseases	282
Pharmacogenomics of Cardiovascular Disorders	282
Modifying the Genetic Risk for MI	283
Management of Heart Failure	283
β -Blockers.....	283
Bucindolol.....	284
BiDil.....	284
Management of Hypertension.....	285
Pharmacogenomics of Diuretic Drugs	286
Pharmacogenomics of ACE Inhibitors	287

Management of Hypertension by Personalized Approach.....	287
Pharmacogenetics of Lipid-Lowering Therapies.....	288
Polymorphisms in Genes Involved in Cholesterol Metabolism.....	288
Role of eNOS Gene Polymorphisms	289
The STRENGTH Study	290
Personalized Management of Women with Hyperlipidemia	291
Thrombotic Disorders	291
Factor V Leiden Mutation.....	291
Anticoagulant Therapy.....	292
Nanotechnology-Based Personalized Therapy of Cardiovascular Diseases	293
Project euHeart for Personalized Management of Cardiovascular Diseases	294
Concluding Remarks.....	294
Summary	295
13 Personalized Management of Miscellaneous Disorders	297
Management of Viral Infections	297
Management of HIV	297
Genetics of Human Susceptibility to HIV Infection.....	297
Pharmacogenomics of Antiretroviral Agents.....	298
Role of Diagnostic Testing in HIV	299
CD4 Counts as a Guide to Drug Therapy for AIDS	299
Drug-Resistance in HIV.....	299
Measurement of Replication Capacity.....	300
Prevention of Adverse Reactions to Antiviral Drugs.....	300
Role of Genetic Variations in Susceptibility to HIV-1.....	301
Pharmacogenetics and HIV Drug Safety	302
Treatment of Hepatitis B.....	302
Treatment of Hepatitis C.....	302
Personalized Management of Tuberculosis (TB).....	304
Personalized Management of Skin Disorders.....	305
Personalized Therapy of Rheumatoid Arthritis (RA)	305
DIATSTAT TM Anti-Cyclic Citrullinated Peptides in RA.....	307
Personalization of COX-2 Inhibitor Therapy.....	307
Personalization of Infliximab Therapy	308
Personalized Therapy of Asthma.....	308
Genetic Polymorphism and Response to β_2 -Adrenergic Agonists	308
Genotyping in Asthma	309
Personalized Approaches in Immunology	310
Pharmacogenetics and Pharmacogenomics of Immunosuppressive Agents.....	311
Personalized Immunosuppressant Therapy in Organ Transplants.....	311
Personalized Management of Pain.....	312
Pharmacogenetics/Pharmacogenomics of Pain.....	313

Mechanism-Specific Management of Pain	314
Preoperative Testing to Tailor Postoperative Analgesic Requirements	314
Personalized Analgesics.....	315
Management of Genetic Disorders	316
Personalized Treatment of Cystic Fibrosis	316
Personalized Management of Gastrointestinal Disorders	317
Personalized Therapy of Inflammatory Bowel Disease.....	317
Personalized Management of Lactose Intolerance	318
Personalized Approach to Addiction	318
Genetic Polymorphism and Management of Alcoholism.....	318
Personalized Therapy for Smoking Cessation	319
Antidepressant Therapy for Smoking Cessation.....	319
Effectiveness of Nicotine Patches in Relation to Genotype.....	319
Personalized Approach to Drug Addiction.....	320
Personalized Approaches to Miscellaneous Problems.....	320
Hormone Replacement Therapy in Women.....	320
Personalized Treatment of Malaria.....	321
Personalized Management of Renal Disease	322
Personalization of Organ Transplantation.....	322
Personalization of Kidney Transplantation.....	323
Personalization of Cardiac Transplantation	323
Prediction of Rejection to Tailor Anti-Rejection Medications	324
Role of Immunological Biomarkers in Monitoring Grafted Patients.....	325
Improved Matching of Blood Transfusion.....	325
Personalized Care of Trauma Patients	326
Personalized Anticoagulation	326
Personalized Hyperbaric Oxygen Therapy	327
Summary	328
14 Personalized Preventive Medicine	329
Introduction.....	329
Personalized Nutrition	330
Nutrigenomics.....	330
Nutrigenomics and Functional Foods	331
Nutrigenomics and Personalized Medicine	332
Nutrition and Proteomics	332
Personalized Diet Prescription.....	333
Summary	333
15 Organization of Personalized Medicine	335
Players in the Development of Personalized Medicine	335
Personalized Medicine Coalition	335
Role of Pharmaceutical Industry.....	336

Production and Distribution of Personalized Medicines.....	338
Role of Biotechnology Companies	339
Role of life Sciences Industries.....	339
Collaboration Between the Industry and the Academia	340
Role of the Clinical Laboratories.....	340
Role of the US Government.....	341
Role of US Government Institutions in Development of	
Personalized Medicine	342
NIH’s Roadmap Initiative for Medical Research.....	342
NIH and Personalized Medicine	343
National Institute of General Medical Sciences.....	343
National Institute of Standards and Technology	344
Role of Academic Institutions in the USA	345
Clinical Proteomics Program	345
Coriell Personalized Medicine Collaborative™	345
Delaware Valley Personalized Medicine Project	346
Evaluation of Genetic Tests and Genomic Applications	347
Genomic-Based Prospective Medicine Project.....	347
Personalized oncology at Massachusetts General Hospital	348
Pharmacogenetics Research Network and Knowledge Base.....	349
Quebec Center of Excellence in Personalized Medicine	349
Southeast Nebraska Cancer Center’s Personalized	
Medicine Network	350
Wisconsin Genomics Initiative	350
Role of Healthcare Organizations and Hospitals	350
Signature Genetics	351
The Mayo Clinic Genetic Database	351
Research Center for Personalized Medicine at	
Mt. Sinai Medical Center.....	352
Role of the Medical Profession.....	352
Education of the Physicians	352
Off-Label Prescribing and Personalized Medicine	353
Medical Education	353
Education of the Public.....	354
Role of the Internet in Development of Personalized Medicine	354
Public Attitude Towards Personalized Medicine	355
Global Scope of Personalized Medicine	356
Personalized Medicine in the Developed Countries	356
US HHSs Supports Personalized Medicine	356
Personalized Medicine in the USA	357
Personalized Medicine in the EU.....	357
UK National Health Service and Medical Genetics	358
Personalized Medicine in the Developing Countries.....	358
Advantages and Limitations of Personalized Medicine.....	359
Summary	361

16 Ethical and Regulatory Aspects of Personalized Medicine	363
Introduction to Ethical Issues.....	363
Ethical Issues of Pharmacogenetics.....	363
Ethical Aspects of Genetic Information.....	364
Ethical Issues of Whole Genome Analysis.....	364
Ethical Aspects of Direct-to-Consumer (DTC) Genetic Services	365
Privacy Issues in Personalized Medicine.....	367
Genetic Information Nondiscrimination Act in the USA.....	367
Genotype-Specific Clinical Trials.....	368
Social Issues in Personalized Medicine.....	368
Race and Personalized Medicine.....	369
Regulatory Aspects.....	371
CLSI Guideline for the Use of RNA Controls in	
Gene Expression Assays.....	372
Microarray Quality Control Project.....	372
Regulatory Aspects of Pharmacogenetics.....	373
Regulation of DTC Genetic Testing.....	374
FDA and Pharmacogenomics.....	375
FDA Guidance for Pharmacogenomic Data Submissions.....	375
Joint Guidelines of the FDA and EU Regulators	
for Pharmacogenomics.....	376
Pharmacogenomic Information in Drug Labels.....	376
FDA guidelines for Pharmacogenomics-Based Dosing.....	377
FDA and Validation of Biomarkers.....	377
FDA and Predictive Medicine.....	378
FDA Regulation of Multivariate Index Assays.....	379
Evaluation of Companion Diagnostics/Therapeutic for Cancer	381
Summary.....	381
17 Economics of Personalized Medicine	383
Introduction.....	383
Perceived Financial Concerns.....	383
Personalized Medicine and Orphan Drug Syndrome.....	384
Commercial Aspects of Pharmacogenomics.....	384
Cost of DNA Testing.....	384
Cost of Sequencing the Human Genome.....	384
Cost of Genotyping.....	387
Cost of Pharmacogenomics-Based Clinical Trials.....	388
Cost of Personalized Healthcare.....	389
Cost of Genetic Testing.....	389
Economics of CYP Genotyping-Based Pharmacotherapy.....	390
Cost of Personalized Medicines.....	390
Lowering the Cost of Healthcare in the USA.....	391
Cost Effectiveness of HIV Genotyping.....	391
Lowering the High Costs of Cancer Chemotherapy.....	391

Reducing the Cost Incurred by Adverse Drug Reactions	392
Overall Impact of Personalized Medicine on Healthcare	392
Summary	392
18 Future of Personalized Medicine	395
Introduction	395
Ongoing Genomic Projects	396
Understanding the Genetic Basis of Diseases	396
Personal Genome Project	396
Genome-Wide Association Studies	397
The 1000 Genomes Project	398
Genomics of Aging in a Genetically Homogeneous Population	399
Translational Science and Personalized Medicine	399
Translation of Genomic Research into Genetic Testing for Healthcare	399
Long-Term Behavioral Effects of Personal Genetic Testing	400
Drivers for the Development of Personalized Medicine	401
Evolution of Medicine as a Driver for Personalized Therapy Markets	402
Personalized Predictive Medicine	402
Opportunities and Challenges	403
Prospects and Limitations of Genetic Testing	403
Challenges in Delivery of Personalized Medicine	404
Pharmacotyping	405
Concluding Remarks about the Future of Personalized Medicine	405
Summary	406
References	407
Index	421



<http://www.springer.com/978-1-4419-0768-4>

Textbook of Personalized Medicine

Jain, K.K.

2009, XXVI, 430 p., Hardcover

ISBN: 978-1-4419-0768-4